DSG's EDC Used in Current Alzheimer's, Parkinson's and Diabetes Trials
MALVERN, Pa.--DSG, a provider of electronic data capture (EDC) solutions, has teamed up with a leading-edge pharmaceutical company to speed the early detection of Alzheimer’s, Parkinson’s, and Diabetes.The focus is on developing molecular imaging products that are leading the way to the early detection of human diseases. DSG’s eCaseLink™ EDC supports three current clinical trials for Alzheimer’s disease, Parkinson’s disease and Diabetes. eCaseLink™ supplies real-time capability to review case documents and metrics across all study sites, significantly increasing clinical trial management speed, while reducing study management costs by as much as 30 percent.DSG’s eCaseLink™ allows the pharmaceutical diagnostic and therapeutic company not only to collect and manage their data in real time, but it also gives them the option to add needed functionality as studies progress. They have found that the innovation of the eCaseLink™ product suite, combined with the experience and dedication of the DSG team, is paying immediate and continued dividends for their clinical trial management process.
High-Dose Ocrevus Falls Short of Primary Endpoint in Relapsing Multiple Sclerosis Trial
April 7th 2025In the Phase III MUSETTE study, a higher dose of intravenous Ocrevus (ocrelizumab) did not provide additional benefit in slowing disability progression compared to the currently approved 600mg dose.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
